Additionally, dapagliflozin, sodium-glucose co-transporter-2 (SGLT-2) inhibitor, has been shown to reduce the composite of cardiovascular death or worsening HF in patients with heart failure with reduced ejection fraction (HFrEF) in the DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) trial (13). Here, SLC5A2 is linked to hydrops fetalis.